Does Avelumab Cause Merkel Cell Carcinoma?

Understanding the Broader Context of Pharmaceutical Safety

General health and science communication has long emphasized the importance of understanding how environmental and pharmaceutical factors interact with human biology. In this broad context, the public has been educated about the balance between therapeutic benefits and potential adverse effects of medical interventions. This foundational knowledge provides a framework for examining specific cases where a treatment’s intended action may raise questions about unintended consequences. One such area of inquiry involves the use of immune checkpoint inhibitors, a class of drugs that modulate the body’s immune response. Among these, Avelumab is approved for the treatment of Merkel cell carcinoma, a rare but aggressive skin cancer. The clinical success of Avelumab in this setting naturally leads to a critical question: could the drug itself, under certain conditions, contribute to the development of the very disease it is meant to treat? This question shifts the focus from general health literacy to a more targeted occupational exposure concern, particularly for healthcare workers, researchers, and manufacturing personnel who may handle Avelumab in their professional environments. Understanding whether such exposure could influence Merkel cell carcinoma risk requires a careful examination of the drug’s mechanism, dosing, and the biological context of exposure, without assuming causation.

Avelumab as a Treatment, Not a Cause

The available evidence does not support a causal relationship in which Avelumab induces or causes the development of Merkel cell carcinoma (MCC). Instead, the evidence consistently describes Avelumab as a therapeutic agent approved for the treatment of MCC, not as a cause of the disease. Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody directed against programmed cell death ligand 1 (PD-L1) and functions as an immune checkpoint inhibitor (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the USA, the EU, and Japan for the treatment of metastatic MCC, making it the first therapeutic agent specifically approved for this indication (https://pubmed.ncbi.nlm.nih.gov/29799096/). Approval was based on the phase II JAVELIN Merkel 200 trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). This indicates that Avelumab is used to treat existing MCC, not to cause it.

Merkel Cell Carcinoma: Etiology and Risk Factors

MCC is described as a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/). It is also characterized as a very rare but highly aggressive cutaneous neuroendocrine carcinoma associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus (https://pubmed.ncbi.nlm.nih.gov/35877101/). The incidence of MCC is increasing, and it is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including Avelumab, have significantly improved treatment outcomes in metastatic disease, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). The evidence does not describe any mechanistic pathway by which Avelumab could cause MCC. Rather, Avelumab is known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). For example, a case report described hypercalcemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on Avelumab, which was managed with corticosteroids, and Avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This illustrates that Avelumab can trigger immune-related side effects but not the initiation of MCC.

Risk Considerations and Treatment Outcomes

Regarding risk considerations, the evidence indicates that approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). For Avelumab-refractory patients, treatment options such as combined ipilimumab and nivolumab have been studied. In a multicenter study, three out of five patients with Avelumab-refractory MCC responded to combined ipilimumab/nivolumab according to RECIST 1.1 (https://pubmed.ncbi.nlm.nih.gov/33439294/). Another study reported that immune checkpoint inhibition has significantly improved treatment outcomes in metastatic disease (https://pubmed.ncbi.nlm.nih.gov/36450381/). These findings highlight that Avelumab is used as a treatment for MCC, and when it fails, alternative therapies are available. The adequacy of warnings regarding Avelumab and MCC is not directly addressed in the provided evidence. However, the evidence consistently positions Avelumab as an approved therapy for MCC, implying that its use is accompanied by standard prescribing information and risk communication for immune checkpoint inhibitors. The evidence does not suggest that Avelumab causes MCC, so warnings about causation would not be applicable.

Conclusion: No Evidence of Causation

Causation-related considerations for affected patients focus on the natural history of MCC and the role of Avelumab as a treatment. Patients with MCC are treated with Avelumab to manage their disease, and the timeline between exposure and documented harm is not relevant because Avelumab is not a cause of MCC. The evidence does not provide any timeline linking Avelumab exposure to the development of MCC. In summary, the evidence firmly establishes Avelumab as a treatment for MCC, not a cause. The disease is associated with ultraviolet light exposure and Merkel cell polyoma virus, and Avelumab is an immune checkpoint inhibitor used to treat it. No evidence supports a causal relationship between Avelumab and the development of MCC.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Can Avelumab cause Merkel cell carcinoma?

No, the available evidence does not support a causal relationship. Avelumab is an immune checkpoint inhibitor approved for the treatment of Merkel cell carcinoma, not a cause of the disease. Studies consistently show it is used to treat existing MCC, and no mechanistic pathway has been identified by which Avelumab could induce MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/).

What are the known risk factors for Merkel cell carcinoma?

Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus. It is a rare but aggressive neuroendocrine cutaneous malignancy with increasing incidence and high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/).

What should I do if I have been exposed to Avelumab and developed Merkel cell carcinoma?

If you have documented Avelumab exposure and a confirmed Merkel cell carcinoma diagnosis, you may request an independent eligibility review through the Information Registry. However, based on current evidence, Avelumab is not known to cause MCC, and such cases would likely be coincidental rather than causal.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel cell carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.